Cargando…
Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers
OBJECTIVE: We examined whether diabetic ketoacidosis (DKA), a serious complication of type 1 diabetes (T1D) was more prevalent among Non-Hispanic (NH) Black and Hispanic patients with T1D and laboratory-confirmed coronavirus disease 2019 (COVID-19) compared with NH Whites. METHOD: This is a cross-se...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928931/ https://www.ncbi.nlm.nih.gov/pubmed/33410917 http://dx.doi.org/10.1210/clinem/dgaa920 |
_version_ | 1783659905300824064 |
---|---|
author | Ebekozien, Osagie Agarwal, Shivani Noor, Nudrat Albanese-O’Neill, Anastasia Wong, Jenise C Seeherunvong, Tossaporn Sanchez, Janine DeSalvo, Daniel Lyons, Sarah K Majidi, Shideh Wood, Jamie R Acharya, Runa Aleppo, Grazia Sumpter, Kathryn M Cymbaluk, Anna Shah, Nirali A Van Name, Michelle Cruz-Aviles, Lisa Alonso, Guy Todd Gallagher, Mary Pat Sanda, Srinath Feuer, Alexis Jamie Cossen, Kristina Rioles, Nicole Jones, Nana-Hawa Yayah Kamboj, Manmohan K Hirsch, Irl B |
author_facet | Ebekozien, Osagie Agarwal, Shivani Noor, Nudrat Albanese-O’Neill, Anastasia Wong, Jenise C Seeherunvong, Tossaporn Sanchez, Janine DeSalvo, Daniel Lyons, Sarah K Majidi, Shideh Wood, Jamie R Acharya, Runa Aleppo, Grazia Sumpter, Kathryn M Cymbaluk, Anna Shah, Nirali A Van Name, Michelle Cruz-Aviles, Lisa Alonso, Guy Todd Gallagher, Mary Pat Sanda, Srinath Feuer, Alexis Jamie Cossen, Kristina Rioles, Nicole Jones, Nana-Hawa Yayah Kamboj, Manmohan K Hirsch, Irl B |
author_sort | Ebekozien, Osagie |
collection | PubMed |
description | OBJECTIVE: We examined whether diabetic ketoacidosis (DKA), a serious complication of type 1 diabetes (T1D) was more prevalent among Non-Hispanic (NH) Black and Hispanic patients with T1D and laboratory-confirmed coronavirus disease 2019 (COVID-19) compared with NH Whites. METHOD: This is a cross-sectional study of patients with T1D and laboratory-confirmed COVID-19 from 52 clinical sites in the United States, data were collected from April to August 2020. We examined the distribution of patient factors and DKA events across NH White, NH Black, and Hispanic race/ethnicity groups. Multivariable logistic regression analysis was performed to examine the odds of DKA among NH Black and Hispanic patients with T1D as compared with NH White patients, adjusting for potential confounders, such as age, sex, insurance, and last glycated hemoglobin A1c (HbA1c) level. RESULTS: We included 180 patients with T1D and laboratory-confirmed COVID-19 in the analysis. Forty-four percent (n = 79) were NH White, 31% (n = 55) NH Black, 26% (n = 46) Hispanic. NH Blacks and Hispanics had higher median HbA1c than Whites (%-points [IQR]: 11.7 [4.7], P < 0.001, and 9.7 [3.1] vs 8.3 [2.4], P = 0.01, respectively). We found that more NH Black and Hispanic presented with DKA compared to Whites (55% and 33% vs 13%, P < 0.001 and P = 0.008, respectively). After adjusting for potential confounders, NH Black patients continued to have greater odds of presenting with DKA compared with NH Whites (OR [95% CI]: 3.7 [1.4, 10.6]). CONCLUSION: We found that among T1D patients with COVID-19 infection, NH Black patients were more likely to present in DKA compared with NH White patients. Our findings demonstrate additional risk among NH Black patients with T1D and COVID-19. |
format | Online Article Text |
id | pubmed-7928931 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-79289312021-03-04 Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers Ebekozien, Osagie Agarwal, Shivani Noor, Nudrat Albanese-O’Neill, Anastasia Wong, Jenise C Seeherunvong, Tossaporn Sanchez, Janine DeSalvo, Daniel Lyons, Sarah K Majidi, Shideh Wood, Jamie R Acharya, Runa Aleppo, Grazia Sumpter, Kathryn M Cymbaluk, Anna Shah, Nirali A Van Name, Michelle Cruz-Aviles, Lisa Alonso, Guy Todd Gallagher, Mary Pat Sanda, Srinath Feuer, Alexis Jamie Cossen, Kristina Rioles, Nicole Jones, Nana-Hawa Yayah Kamboj, Manmohan K Hirsch, Irl B J Clin Endocrinol Metab Clinical Research Articles OBJECTIVE: We examined whether diabetic ketoacidosis (DKA), a serious complication of type 1 diabetes (T1D) was more prevalent among Non-Hispanic (NH) Black and Hispanic patients with T1D and laboratory-confirmed coronavirus disease 2019 (COVID-19) compared with NH Whites. METHOD: This is a cross-sectional study of patients with T1D and laboratory-confirmed COVID-19 from 52 clinical sites in the United States, data were collected from April to August 2020. We examined the distribution of patient factors and DKA events across NH White, NH Black, and Hispanic race/ethnicity groups. Multivariable logistic regression analysis was performed to examine the odds of DKA among NH Black and Hispanic patients with T1D as compared with NH White patients, adjusting for potential confounders, such as age, sex, insurance, and last glycated hemoglobin A1c (HbA1c) level. RESULTS: We included 180 patients with T1D and laboratory-confirmed COVID-19 in the analysis. Forty-four percent (n = 79) were NH White, 31% (n = 55) NH Black, 26% (n = 46) Hispanic. NH Blacks and Hispanics had higher median HbA1c than Whites (%-points [IQR]: 11.7 [4.7], P < 0.001, and 9.7 [3.1] vs 8.3 [2.4], P = 0.01, respectively). We found that more NH Black and Hispanic presented with DKA compared to Whites (55% and 33% vs 13%, P < 0.001 and P = 0.008, respectively). After adjusting for potential confounders, NH Black patients continued to have greater odds of presenting with DKA compared with NH Whites (OR [95% CI]: 3.7 [1.4, 10.6]). CONCLUSION: We found that among T1D patients with COVID-19 infection, NH Black patients were more likely to present in DKA compared with NH White patients. Our findings demonstrate additional risk among NH Black patients with T1D and COVID-19. Oxford University Press 2020-12-19 /pmc/articles/PMC7928931/ /pubmed/33410917 http://dx.doi.org/10.1210/clinem/dgaa920 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_modelThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) |
spellingShingle | Clinical Research Articles Ebekozien, Osagie Agarwal, Shivani Noor, Nudrat Albanese-O’Neill, Anastasia Wong, Jenise C Seeherunvong, Tossaporn Sanchez, Janine DeSalvo, Daniel Lyons, Sarah K Majidi, Shideh Wood, Jamie R Acharya, Runa Aleppo, Grazia Sumpter, Kathryn M Cymbaluk, Anna Shah, Nirali A Van Name, Michelle Cruz-Aviles, Lisa Alonso, Guy Todd Gallagher, Mary Pat Sanda, Srinath Feuer, Alexis Jamie Cossen, Kristina Rioles, Nicole Jones, Nana-Hawa Yayah Kamboj, Manmohan K Hirsch, Irl B Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers |
title | Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers |
title_full | Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers |
title_fullStr | Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers |
title_full_unstemmed | Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers |
title_short | Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers |
title_sort | inequities in diabetic ketoacidosis among patients with type 1 diabetes and covid-19: data from 52 us clinical centers |
topic | Clinical Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928931/ https://www.ncbi.nlm.nih.gov/pubmed/33410917 http://dx.doi.org/10.1210/clinem/dgaa920 |
work_keys_str_mv | AT ebekozienosagie inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT agarwalshivani inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT noornudrat inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT albaneseoneillanastasia inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT wongjenisec inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT seeherunvongtossaporn inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT sanchezjanine inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT desalvodaniel inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT lyonssarahk inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT majidishideh inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT woodjamier inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT acharyaruna inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT aleppograzia inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT sumpterkathrynm inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT cymbalukanna inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT shahniralia inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT vannamemichelle inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT cruzavileslisa inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT alonsoguytodd inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT gallaghermarypat inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT sandasrinath inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT feueralexisjamie inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT cossenkristina inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT riolesnicole inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT jonesnanahawayayah inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT kambojmanmohank inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters AT hirschirlb inequitiesindiabeticketoacidosisamongpatientswithtype1diabetesandcovid19datafrom52usclinicalcenters |